Clinical Trials Logo

Filter by:
NCT ID: NCT05753878 Completed - COVID-19 Clinical Trials

A Study to Evaluate the Safety and Pharmacokinetics of HH-120 Nasal Spray in Healthy Volunteers

Start date: November 8, 2022
Phase: Phase 1
Study type: Interventional

This is a clinical study evaluating the safety, tolerability, pharmacokinetic (PK) characteristics and immunogenicity of HH-120 nasal spray in healthy subjects. This study is divided into two parts: Part A is of open-label design and mainly aims to assess the local distribution and PK in nasal cavity of HH-120 nasal spray, subjects from 10 cohorts are sequentially enrolled to perform either nasal endoscopic examination or nasal/ nasopharyngeal samples collection at different time points post administration. Part B mainly aims to assess the safety, systematic pharmacokinetic and immunogenicity after multiple dosing of HH-120 nasal spray, subjects are randomly assigned (3:1) to HH-120 and placebo groups.

NCT ID: NCT05753865 Not yet recruiting - Clinical trials for Advanced Breast Cancer

A Study to Evaluate the Efficacy and Safety in Patients With Advanced Breast Cancer Treated With SYHX2011 Compared to Paclitaxel for Injection (Albumin-bound)

Start date: May 1, 2023
Phase: Phase 3
Study type: Interventional

The main purpose of this study is to evaluate the efficacy and safety in patients with advanced breast cancer treated with SYHX2011 versus paclitaxel for injection (albumin-bound).

NCT ID: NCT05753826 Recruiting - Ovarian Neoplasms Clinical Trials

Adebrelimab Combined With Fuzuloparib in the Treatment of Patients With Recurrent Platinum-resistant Ovarian Cancer.

Start date: August 1, 2023
Phase: Phase 2
Study type: Interventional

This is a single-arm, exploratory study. People with recurrent platinum-resistant ovarian cancer who have not received any previous systemic antitumor therapy for ovarian cancer were selected to evaluate the efficacy and safety of adebrelimab combined with fuzuloparib.

NCT ID: NCT05753774 Recruiting - Clinical trials for Functional Gastrointestinal Disorders

Effect of Fecal Microbiota Transplantation (FMT) in Pediatric Functional Gastrointestinal Disorders

FGIDs
Start date: August 1, 2022
Phase: N/A
Study type: Interventional

Safety and efficacy of FMT in Pediatric Functional

NCT ID: NCT05753696 Recruiting - Blood Pressure Clinical Trials

Azilsartan in Patients With Diabetic Kidney Disease and Hypertension

Start date: April 1, 2023
Phase: N/A
Study type: Interventional

Hypertension is the most common complication in patients with diabetes nephropathy. Strengthening blood pressure and blood sugar control is the basic treatment for patients with diabetes nephropathy. Angiotensin receptor blocker (ARB) and angiotensin-converting enzyme inhibitor (ACEI) are the first line drugs recommended in domestic and international guidelines for diabetes patients to control hypertension. As a new ARB drug, azilsartan has been found to have better antihypertensive effect than other ARB drugs. However, due to the limited sample size and study time, azilsartan has no significant advantage over other ARB drugs in terms of renal protection effect, and has not been systematically studied in diabetes nephropathy population. This study is intended to evaluate the effect of azilsartan on proteinuria and blood pressure improvement in patients with diabetes nephropathy and hypertension through clinical randomized controlled study, so as to accumulate evidence-based evidence of azilsartan in the comprehensive management of heart and kidney protection in this group of people, and promote the development of comprehensive treatment for patients with metabolic disease and renal injury combined with hypertension. This study will compare the advantages and disadvantages of azilsartan and classical ARB drug losartan potassium in terms of proteinuria, blood pressure control and renal function protection in patients with diabetes nephropathy and hypertension; We propose that the main indicator is the change of urinary albumin/creatinine ratio relative to the baseline, and the secondary indicator is the change of 24-hour urinary protein relative to the baseline; Change of blood pressure relative to baseline; Renal function, electrolyte and blood glucose.

NCT ID: NCT05753644 Recruiting - Atrial Fibrillation Clinical Trials

The Effect of Preoperative SGB on POAF After VATS

Start date: March 27, 2023
Phase: N/A
Study type: Interventional

The aim of this study is to test if stellate ganglion block can decrease the incidence of atrial fibrillation after video-assisted thoracoscopic surgery and the way it works.

NCT ID: NCT05753566 Recruiting - Prostate Cancer Clinical Trials

Rezvilutamide in Patients With Biochemical Recurrence After Radical Prostatectomy for Prostate Cancer

Start date: March 2023
Phase: Phase 2
Study type: Interventional

To evaluate the efficacy and safety of rezvilutamide in combination with androgen deprivation therapy(ADT) and standard salvage radiation therapy(SRT) or rezvilutamide in combination with ADT in prostate cancer patients with biochemical recurrence of prostate-specific antigen(PSA) persistence after radical prostatectomy(RP).

NCT ID: NCT05753332 Active, not recruiting - Clinical trials for Exposure to Polluted Air

Association Between PM2.5 and Ferroptosis

Start date: December 1, 2022
Phase:
Study type: Observational [Patient Registry]

This cohort study aims to discover the possible effects of PM2.5 exposures on the Nrf2- dependent ferroptosis pathway. This observational cohort's main question is whether PM2.5 exposures will affect the Nrf2- dependent ferroptosis pathway. Participants will be divided into two groups: the control group and the air pollution to detect the biomarkers of the Nrf2- dependent ferroptosis pathway.

NCT ID: NCT05753280 Completed - Chronic Hepatitis b Clinical Trials

Effect of Serum Vitamin D Level on the Efficacy of Peg-interferon Treatment in CHB

Start date: December 1, 2018
Phase: Phase 4
Study type: Interventional

In recent years, vitamin D (VD) has received much attention in the fields of host immune regulation, inflammation, fibrosis, cell proliferation and differentiation and tumor. VD works by binding to the vitamin D receptor (VDR). VDR is mainly distributed in giant cells, dendritic cells, T cells and lymphocytes. Four SNPs of VDRS have been most studied: TaqI (rs731236), FokI (rs10735810), ApaI (rs7975232), and BsmI (rs1544410). At present, more and more patients have been treated with oral nucleotide/nucleoside analogues (NAs) with direct antiviral drugs in China, and a large part of them show low expression of HBsAg. Clinical cure can be pursued for these patients, that is, HBsAg turns negative. A number of studies have been carried out at home and abroad. In this study, We will recruit CHB patients with low HBsAg levels. They all will receive pegylated interferon treatment and were randomly assigned to a vitamin D treatment or a control group. A final assessment will be made to determine whether vitamin D levels would affect the clearance rate of HBsAg.

NCT ID: NCT05753241 Completed - COVID-19 Clinical Trials

the Relationship Between Allergic Rhinitis and the Risk of Symptom in Patients With Mild COVID-19

Start date: November 10, 2022
Phase:
Study type: Observational [Patient Registry]

At present, most studies mainly focussed on severe patients, and there was no comparison of symptom differences between AR patients and healthy people with mild infection to evaluate the symptoms of AR patients during infection and to provide preventive treatment in advance. So this experiment was designed.